

2024 年英文論文業績

1. Sugita J, Morita K, Konuma T, **Yanada M**. Allogeneic hematopoietic cell transplantation from alternative donors in acute myeloid leukemia. **Ann Hematol.** 2024;103:4851-4868.
2. Mizuno S, Hosoi H, Takami A, Kawata T, Doki N, Takeda W, Tanaka M, Nishida T, Uchida N, Hasegawa Y, Sawa M, Ota S, Onizuka M, Nakamae H, Asada N, Fukuda T, Yoshimitsu M, Kanda Y, Ohbiki M, Atsuta Y, Konuma T, **Yanada M**. Reappraising the prognostic relevance of cytogenetic risk in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. **Ann Hematol.** 2024;103:5903-5913.
3. Moriguchi M, Nakamae H, Nishimoto M, Sugita J, **Yanada M**, Toubai T, Hasegawa Y, Hino M, Nishida T, Kurita N, Sawa M, Fukuda T, Jinguji A, Ota S, Matsuoka KI, Eto T, Hiramoto N, Ando T, Kawamura K, Kanda Y, Atsuta Y, Ohbiki M, Nakasone H, Konuma T. Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia. **Br J Haematol.** 2024;205:2376-2386.
4. **Yanada M**. Leucocytosis during all-trans retinoic acid and arsenic trioxide treatment in acute promyelocytic leukaemia. **Br J Haematol.** 2024;205:1672-1673.
5. Shibata S, Arai Y, Kondo T, Mizuno S, Yamasaki S, Akasaka T, Doki N, Ota S, Maruyama Y, Matsuoka KI, Nagafuji K, Eto T, Tanaka T, Ohigashi H, Nakamae H, Onizuka M, Fukuda T, Atsuta Y, **Yanada M**. Prognostic factors in haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia. **Cytotherapy.** 2024;26:592-598.
6. Sugita J, **Yanada M**. Current status of conditioning regimens in haploidentical hematopoietic cell transplantation. **Hematology.** 2024;29(1):2332866.
7. Matsunaga N, Suzuki T, Nishitarumizu N, Nakanishi Y, Kondo A, **Kato Y**, Ebina T, Marumo Y, Nakamura T, Nakashima T, Kinoshita S, Narita T, Ri M, Kusumoto S, Komatsu H, Iida S. Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single Institution. **Clin Lymphoma Myeloma Leuk.** 2024 Aug;24(8):531-536.e1.
8. Mizuno S, Takami A, Kawamura K, Harada K, Masayoshi M, Yano S, Ito A,

- Ozawa Y, Ouchi F, Ashida T, Nawa Y, Ichinohe T, Fukuda T, Atsuta Y, **Yanada M**. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with BCR::ABL1 fusion. **eJHaem**. 2024;5:369-378.
9. **Yanada M**, Yano S, Kuwatsuka Y, Kawamura K, Fukuda T, Ichinohe T, Hashii Y, Goto H, Kato K, Ishimaru F, Sato A, Onizuka M, Matsuo K, Ito Y, Yanagisawa A, Ohbiki M, Tabuchi K, Atsuta Y, Kanda J, Konuma T. The effect of center experience on allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia. **Bone Marrow Transplant**. 2024;59:541-549.
10. **Yanada M**, Yamasaki S, Kondo T, Kawata T, Harada K, Uchida N, Doki N, Yoshihara S, Katayama Y, Eto T, Tanaka M, Takada S, Kawakita T, Nishida T, Ota S, Serizawa K, Onizuka M, Kanda Y, Fukuda T, Atsuta Y, Konuma T. Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission. **Leukemia**. 2024;38:513-520.
11. Makita S, Ota S, Mishima Y, Usuki K, Ennishi D, **Yanada M**, Fukuhara N, Yamamoto R, Takamine A, Nohara G, Izutsu K. Japanese phase Ib study of the oral PI3K- δ and - γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. **Int J Hematol**. 2024;119:156-163.
12. Konuma T, Yamasaki S, Ishiyama K, Mizuno S, Hayashi H, Uchida N, Shimabukuro M, Tanaka M, Kuriyama T, Onizuka M, Ishiwata K, Sawa M, Tanaka T, Ohigashi H, Fujiwara SI, Matsuoka KI, Ota S, Nishida T, Yoshinobu K, Fukuda T, Atsuta Y, Nakasone H, **Yanada M**. Comparison of allogeneic transplant outcomes between matched sibling donors and alternative donors in patients over 50 years of age with acute myeloid leukemia: 8/8 allele-matched unrelated donors and unrelated cord blood provide better leukemia-free survival compared with matched sibling donors during non-remission status: MSD vs alternative donors transplant for patients over 50 years of age with AML. **Transplant Cell Ther**. 2024;30:215.e1-215.e18.